12 Month Progress Report 30/04/2019-30/04/2020

ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also known as ERC1671/SITOIGANAP) towards commercialization. Major progress has been made in several areas: (Read more)